Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.

doi:10.1093/neuonc/noab081

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.

Neuro-oncology - 2 Nov 2021

Yu Yao, Villanueva-Meyer Javier, Grimmer Matthew R, Hilz Stephanie, Solomon David A, Choi Serah, Wahl Michael, Mazor Tali, Hong Chibo, Shai Anny, Phillips Joanna J, Wainer Bruce H, McDermott Michael, Haas-Kogan Daphne, Taylor Jennie W, Butowski Nicholas, Clarke Jennifer L, Berger Mitchel S, Molinaro Annette M, Chang Susan M, Costello Joseph F, Oberheim Bush Nancy Ann

Abstract excerpt

BACKGROUND: Chemotherapy improves overall survival after surgery and radiotherapy for newly diagnosed high-risk IDH-mutant low-grade gliomas (LGGs), but a proportion of patients treated with temozolomide (TMZ) will develop recurrent tumors with TMZ-induced hypermutation. We aimed to determine the prevalence of TMZ-induced hypermutation at recurrence and prognostic implications. METHODS: We sequenced recurrent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Metastases and Treatment

Share to Brain Neoplasms

Share to Glioma

Share to Glioma Diagnosis and Treatment

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 33823014
DOI: 10.1093/neuonc/noab081
PMCID: PMC8563321

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.PMID 33823014Read ↗

Temozolomide-associated hypermutation in gliomas.Semantic proximity Read ↗

MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrenceSemantic proximity Read ↗

The epigenetic evolution of gliomas is determined by their IDH1 mutation status and treatment regimenSemantic proximity Read ↗

Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysisSemantic proximity Read ↗

Glioma progression is shaped by genetic evolution and microenvironment interactions.Semantic proximity Read ↗

Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent GliomaSemantic proximity Read ↗

The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen.Semantic proximity Read ↗

Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant gliomaSemantic proximity Read ↗

Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas.Semantic proximity Read ↗

A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence.Semantic proximity Read ↗

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.Semantic proximity Read ↗

Genomic alterations of oligodendrogliomas at distant recurrence.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.